NCT00555971View on ClinicalTrials.gov

Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

PHASE4CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Aspirin Sensitivity

Interventions

DRUG

Omalizumab

Subjects randomized to Omalizumab prior to aspirin desensitization

DRUG

placebo

Subjects randomized to Placebo prior to aspirin desensitization

Trial Locations (1)

44195

The Cleveland Clinic, Cleveland

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

David Lang

OTHER